arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

uniQure N.V.

QURE
$46.38 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

uniQure N.V. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.7B
Dividend Yield
Revenue Growth -40.6%
Op. Margin None
ROIC -70.4%
FCF / Share $-3.10
Trailing P/E
Price / Book 14.5x
FCF Yield
Debt / Equity 0.36
info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.10M
↓ -40.6%
Net Income Profit after all expenses
$-198.97M
↑ +16.9%
Operating Margin Operating profit as % of sales
-134.4%
↓ -326.8%
FCF / Share Free cash flow per share
$-3.10
↑ +18.9%
Long-Term Debt Long-term obligations
$71.92M
↑ +40.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
9
Financial Health
46
Cash Quality
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 44 quarters